Challenges in Diagnosis and Management of Severe Aortic Stenosis with Coexisting Cardiac Amyloidosis: A Case Report

Clicks: 2
ID: 320471
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #231 of 261 articles by views in European Heart Journal - Case Reports

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 261 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Abstract Background Transthyretin amyloid cardiomyopathy (ATTR-CM) coexists in up to 15% of elderly patients with severe aortic stenosis (AS), presenting complex diagnostic and therapeutic challenges due to overlapping clinical phenotypes. Case Summary An 85-year-old female presented with a two-month history of heart failure and a previous medical history of total knee replacement. Echocardiography and computed tomography confirmed severe AS, alongside left ventricular hypertrophy out of proportion to the valvular load and an “apical sparing” strain pattern. Due to the accompanying red flags, a Tc99m-PYP bone scintigraphy was done. This showed a grade 3 cardiac uptake, and further testing confirmed wild-type ATTR-CM. Given her recent symptom onset, preserved ejection fraction, and high-gradient AS, the Heart Team prioritized transcatheter aortic valve implantation (TAVI). Following a successful procedure, she demonstrated excellent functional recovery at one month, which clinically justified the subsequent initiation of transthyretin stabilizers. Discussion Concomitant ATTR-CM must be suspected in elderly AS patients presenting with disproportionate hypertrophy or other clinical/imaging “red flags”. A sequential management strategy—prioritizing TAVI to relieve the hemodynamic bottleneck, followed by clinical reassessment—can effectively identify appropriate candidates for long-term, disease-modifying transthyretin stabilizer therapy.
Reference Key
openalex_W7167911572 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Rengin Çetin Güvenç, Tolga Sinan Güvenç, Müslüm Şahin
Journal European Heart Journal - Case Reports
Year 2026
DOI
10.1093/ehjcr/ytag511
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.